After the impressive tumor-shrinking data shown by Amgen (AMGN) from its KRAS-targeted cancer drug at the recently completed ASCO meeting, attention — and pressure — now shift to Mirati Therapeutics (MRTX) and its competing KRAS blocker.

Mirati is administering its drug called MRTX849 to patients with solid tumors right now. The first data reveal from the early-stage clinical trial is coming later this year. Mirati isn’t being more precise on timing, but investor expectations are running high, which means this trial readout is now shaping up to be one of the most important stock-moving catalysts remaining on the 2019 biotech calendar.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy